Embecta Corp.
Embecta Corp. (also referred to herein as "Embecta") is a leading global medical device company, primarily focused on providing solutions to improve the health and well-being of people living with diabetes. All references in this Form 10-K to "Embecta", "the Company", "we", "our" or "us" refer to Embecta Corp., a Delaware corporation, and its subsidiaries, unless otherwise indicated by the cont…
$6.27
-$0.18 (-2.79%)
EOD Oct 16, 2026
22.41% operating margin is above average. ROIC at 13.09%.
Revenue declined 3.8% YoY. Margins deteriorated 3.5pp alongside, both lines moving the wrong way.
Net debt of $1.22B represents 6.7x FCF, leverage limits flexibility. Operating margin contracted 3.5pp YoY, cost discipline may be slipping.
4.3x earnings, 2.2x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$1.02B
▼ -3.8% YoY
Net Income (TTM)
$88M
▲ +21.8% YoY
Op. Margin
23.04%
▼ -3.5pp YoY
ROIC
13.76%
▼ -0.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$165M
▲ +816.6% YoY
Op. Cash Flow (TTM)
$174M
▲ +437.0% YoY
Net Debt
$1.29B
Cash & Equiv.
$215M
5Y CAGR: -0.1%
5Y CAGR: -16.8%
Continue Research
SourceComputed from the 10-Q filed 31 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 18 Sept 2026. How this is calculated.
Price from market data, last close as of 16 Oct 2026. Fiscal year ends Sep. Sector medians are approximate S&P 500 benchmarks and update periodically.
Is Embecta (EMBC) overvalued?
At a P/E of 4.3 and a price-to-free-cash-flow of 2.2, Embecta (EMBC) trades below a two-stage DCF intrinsic value of about $26.75 per share, so at $6.27 the stock looks undervalued (326.7% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Embecta scores 37/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 7.7%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
What is Embecta's fair value?+
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $26.75 per share for EMBC, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $20.07. At today's $6.27, that puts the stock about 326.7% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Is Embecta a high-quality business?+
Embecta scores 37 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 23.0% operating margin and a 13.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Does Embecta (EMBC) pay a dividend, and how much?+
Yes, Embecta pays a regular dividend of about $0.46 per share per year (typically in quarterly installments), a yield of roughly 7.7% at the current price. That is a payout ratio of about 31.1% of earnings, so the dividend is amply covered by earnings. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For EMBC's full payout history, growth streak and dividend-safety score, see the dividends tab.
Is Embecta a good stock to buy right now?+
That depends on valuation and quality together, not either alone. EMBC currently trades below its estimated intrinsic value and scores 37/100 on quality (lower-quality). It also yields about 7.7%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.
Related stocks: Surgical & Medical Instruments & Apparatus
Spot a number that looks wrong?
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.